Imperva (IMPV) Misses Q2 EPS by 6c, FY Guidance Falls Short

Imperva (NYSE: IMPV) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $57.9 million versus the consensus estimate of $59.11 million.

GUIDANCE:

Imperva sees FY2016 EPS of ($0.82)-($0.78). Imperva sees FY2016 revenue of $248.6-250.6 million, versus the consensus of $276.28 million.

For earnings history and earnings-related data on Imperva (IMPV) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch